Literature DB >> 3712285

Behavioral and neurochemical evaluation of phenylpropanolamine.

W L Woolverton, C E Johanson, R de la Garza, S Ellis, L S Seiden, C R Schuster.   

Abstract

(+/-)-Phenylpropanolamine (PPA), a widely available anorectic and decongestant, was evaluated in several behavioral paradigms in rhesus monkeys and for central nervous system neurotoxicity in rats. PPA (1-30 mg/kg intragastric) reduced food intake in rhesus monkeys but was not self-administered i.v. (0.3-10 mg/kg/injection) by monkeys experienced in drug self-administration. PPA (30-100 mg/kg intragastric) resulted in amphetamine-like responding in two of four monkeys trained in a drug discrimination paradigm to discriminate d-amphetamine from saline. In rats, a 4-day injection regimen of high doses of PPA (200 and 400 mg/kg/day) resulted in approximately a 20% depletion of dopamine in the frontal cortex but failed to deplete dopamine, norepinephrine or serotonin in any other brain region studied. Thus, PPA is an effective anorectic in rhesus monkeys that, based upon drug discrimination results, would be expected to have limited amphetamine-like subjective effects and only at doses well in excess of effective anorectic doses. However, based upon self-administration results, PPA would not be predicted to have amphetamine-like dependence potential. Moreover, repeated administration of PPA did not produce the severe central nervous system neurotoxicity associated with many other amphetamine congeners.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3712285

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials.

Authors:  Sharan R Srinivasan; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

2.  Trends in drug discrimination research analysed with a cross-indexed bibliography, 1984-1987.

Authors:  I P Stolerman; F Rasul; P J Shine
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Muscular and cardiorespiratory effects of pseudoephedrine in human athletes.

Authors:  N D Gill; A Shield; A J Blazevich; S Zhou; R P Weatherby
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

Review 4.  Drug discrimination by humans compared to nonhumans: current status and future directions.

Authors:  J B Kamien; W K Bickel; J R Hughes; S T Higgins; B J Smith
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Phenylpropanolamine: reinforcing and subjective effects in normal human volunteers.

Authors:  L D Chait; E H Uhlenhuth; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Similarities between the stimulus properties of phenylpropanolamine and amphetamine.

Authors:  F Lee; I Stafford; B G Hoebel
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  The discriminative stimulus properties of legal, over-the-counter stimulants administered singly and in binary and ternary combinations.

Authors:  D V Gauvin; K R Moore; B D Youngblood; F A Holloway
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Drug discrimination studies in rats with caffeine and phenylpropanolamine administered separately and as mixtures.

Authors:  E A Mariathasan; I P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 9.  Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.

Authors:  Jie Jiang; John Ravits
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.